MedTrace Logo

Clinical Tolerance to a Live Attenuated Vaccine Against Influenza (Flumist®) in a Population Allergic to Eggs

NCT02142491 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 124

Last updated 2014-05-20

No results posted yet for this study

Summary

The objective of this study is to verify the clinical tolerance to the vaccine Flumist (intranasal live attenuated influenza vaccine) in a population of egg allergic children. More specifically, the investigators want to estimate the risk of severe allergic reaction arising within 24 hours following the vaccination of egg allergic with Flumist.

Conditions

  • Egg Allergy

Sponsors & Collaborators

  • Institut National en Santé Publique du Québec

    collaborator OTHER

  • St. Justine's Hospital

    lead OTHER

Principal Investigators

  • Anne Des Roches, MD · St. Justine's Hospital

  • Gaston De Serres, MD · Santé Publique du Québec

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-02-28
Completion
2014-05-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02142491 on ClinicalTrials.gov